12.16

1.94% -0.24

After Hours: 12.13 -0.03 -0.25%

Contineum Therapeutics Inc (CTNM)

Overview News Price History Discussions Forecast

Contineum Therapeutics Inc stock is traded at $12.16, with a volume of 200.88K. It is down -1.94% in the last 24 hours and down -11.37% over the past month. Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Previous Close:

$12.40

Open:

$12.3

24h Volume:

200.88K

Relative Volume:

0.76

Market Cap:

$454.62M

Revenue:

$50.00M

Net Income/Loss:

$-58.44M

P/E Ratio:

-6.2273

EPS:

-1.9527

Net Cash Flow:

$-57.73M

1W Performance:

+7.61%

1M Performance:

-11.37%

6M Performance:

+5.92%

1Y Performance:

+209.41%

1-Day Range:

$11.87

$13.10

1-Week Range:

$11.35

$13.32

52-Week Range:

$3.57

$16.33

Contineum Therapeutics Inc Stock (CTNM) Company Profile

Name

Contineum Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

(858) 333-5280

Address

3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

CTNM's Discussions on Twitter

Compare CTNM vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CTNM Contineum Therapeutics Inc	12.16	475.55M	50.00M	-58.44M	-57.73M	-1.9527
VRTX Vertex Pharmaceuticals Inc	458.99	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	607.93	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	892.26	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.72	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.77	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-13-25	Initiated	Leerink Partners	Outperform
Sep-25-25	Initiated	Leerink Partners	Outperform
Jun-20-25	Initiated	William Blair	Outperform
Oct-22-24	Initiated	Robert W. Baird	Outperform
Apr-30-24	Initiated	Morgan Stanley	Overweight
Apr-30-24	Initiated	RBC Capital Mkts	Outperform
Apr-30-24	Initiated	Stifel	Buy

View All

Contineum Therapeutics Inc Stock (CTNM) Latest News

Jun 16, 2026

Number of shareholders of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView

Jun 16, 2026

Jun 14, 2026

CTNM Q1 2026 Earnings: Narrower-than-Expected Loss Surprises MarketsProfit Announcement - newsline.com

Jun 14, 2026

Jun 09, 2026

CTNM: PIPE-791 advances in IPF with strong differentiation, robust pipeline, and solid financial runway - TradingView

Jun 09, 2026

CTNM: PIPE-791 advances in IPF with best-in-class potential, strong safety, and robust clinical momentum - TradingView

Jun 09, 2026

Jun 02, 2026

Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance

Jun 02, 2026

Jun 01, 2026

Contineum Therapeutics CSO Daniel Lorrain sells $54,862 in stock - Investing.com

Jun 01, 2026

Contineum Therapeutics (CTNM) CSO sells 4,170 shares under 10b5-1 plan - Stock Titan

Jun 01, 2026

CTNM insider 10b5-1 sales recorded by Morgan Stanley (CTNM) - Stock Titan

Jun 01, 2026

Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference - Weekly Voice

Jun 01, 2026

May 29, 2026

CTNM Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesEarnings Turnaround - newsline.com

May 29, 2026

May 28, 2026

Contineum Therapeutics, Inc.Common stock (CTNM) Stock Price, News, Quote & History - FinancialContent

May 28, 2026

Contineum Therapeutics (CTNM) Retreats 1.08% – Key Support Level in FocusModified Schiff - The Legal Advocate

May 28, 2026